DGX vs GH
Quest Diagnostics and Guardant Health, Inc., both Healthcare
Quest Diagnostics is the larger company at $22B against $19B. Over the past year GH returned +183% against +28% for DGX. The RyuScore puts DGX ahead, 63 against 13 out of 100.
| Figure | DGX | GH |
|---|---|---|
| Last close | $231 | $167 |
| Market cap | $22B | $19B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 24.5 | n/a |
| 1-year return | +28% | +183% |
| 5-year return | +65% | +32% |
| RyuScoresector-relative, 1–10 | 63/100 | 13/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Quest Diagnostics
Revenue of $3.0B in Q2 2026, net income $320M. Its largest reported line is Diagnostic Information Services Business, 98% of the disclosed total.
Guardant Health, Inc.
Revenue of $335M in Q2 2026, net income null. Its largest reported line is Oncology, 65% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.